Comparison 12. Prolonged steroid therapy (7 months) for relapsing nephrotic syndrome.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number with relapses	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
1.1 Relapse by 6 months	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 Relapse by 12 months	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.3 Relapse by 2 years	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.4 Relapse by 3 years	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Relapse rate/patient/y	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
2.1 Relapse rate at 1 year	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 Relapse rate at 2 years	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.3 Relapse rate at 3 years	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
3 Number with frequently relapsing or steroid dependent nephrotic syndrome	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
4 Cumulative steroid dose	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
4.1 After 1 year	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 After 2 years	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
4.3 After 3 years	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
5 Adverse effects	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
5.1 Number with hypertension	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
5.2 Number with growth failure	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]